Liraglutide
GLP-1 Receptor Agonist (Victoza/Saxenda)
31 Amino Acids · MW: 3,751.20 Da
Amino Acids
31
Molecular Weight
3,751.20 Da
Half-life
~13 hours
Research Score
4.6
Studies
890
Storage
N/A
What is Liraglutide?
Liraglutide is an FDA-approved GLP-1 receptor agonist available as Victoza (diabetes) and Saxenda (weight management). It was the first GLP-1 agonist approved specifically for chronic weight management. While newer agents show greater efficacy, liraglutide paved the way for the GLP-1 revolution.
Key Benefits & Mechanisms
FDA-approved for weight management
Proven glycemic control
Cardiovascular risk reduction (LEADER trial)
Well-established safety profile
Appetite suppression
Improved metabolic biomarkers
Daily dosing allows precise titration
Research Summary
Liraglutide has extensive Phase III evidence (SCALE, LEADER programs). FDA-approved with a robust long-term safety database. LEADER trial demonstrated cardiovascular benefit. First-generation GLP-1 for weight loss with well-characterized efficacy (5-8% body weight reduction).
Related Peptides
Semaglutide
GLP-1 Receptor Agonist
Semaglutide is a GLP-1 receptor agonist with proven efficacy for weight management and glycemic control. FDA-approved as Ozempic (diabetes) and Wegovy (weight management), it mimics the incretin hormone GLP-1 to regulate appetite and blood sugar.
MetabolicTirzepatide
GIP/GLP-1 Dual Receptor Agonist
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). It offers superior weight loss compared to GLP-1-only agonists by targeting two incretin pathways simultaneously.
MetabolicAOD-9604
Anti-Obesity Drug (Modified GH Fragment)
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 177-191) specifically designed for fat metabolism. It stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, making it a targeted fat-loss peptide without typical GH side effects.
MetabolicTesamorelin
Synthetic Growth Hormone Releasing Hormone
Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved as Egrifta for HIV-associated lipodystrophy, it reduces visceral adipose tissue while maintaining peripheral fat and improving body composition. Produces physiological GH release.
Metabolic